Is compounded semaglutide FDA-approved?

No. Compounded semaglutide is NOT FDA-approved as a finished product. The FDA approves the active ingredient (semaglutide) and the finished brand products (Wegovy, Ozempic, Rybelsus). Compounded versions use the same active ingredient but the FDA has not reviewed the specific compounded formulation for safety, potency, or quality. Compounding is legal under specific circumstances per 503A and 503B pharmacy rules.

Is compounded semaglutide still legal in 2026?

Yes, compounding under traditional 503A pharmacy rules (per-patient prescriptions) remains legal. The mass-compounding pathway that operated during the 2023-2024 FDA shortage list narrowed substantially after FDA resolved the semaglutide shortage in February 2025. Major telehealth providers continue offering compounded semaglutide for existing patients while increasingly routing new patients to FDA-approved alternatives.

What is the difference between semaglutide and semaglutide sodium?

Semaglutide is the FDA-approved active pharmaceutical ingredient (API). Semaglutide sodium is a salt form that the FDA has explicitly stated is NOT an approved form for compounding. Reputable compounding pharmacies use base semaglutide; salt forms have been flagged by FDA as potentially unsafe due to lack of safety data. Always verify your prescription specifies "semaglutide" (not "semaglutide sodium").

How do I verify a compounding pharmacy is legitimate?

Three checks: (1) Confirm state pharmacy license — every state's Board of Pharmacy has a public license lookup. (2) Look for PCAB accreditation (Pharmacy Compounding Accreditation Board) — voluntary but indicates quality systems. (3) For 503B outsourcing facilities, check FDA's 503B registered facility list. Avoid pharmacies that ship without a real prescription, claim FDA approval of their compound, or sell semaglutide sodium.

Can I get compounded semaglutide cheaper than FDA-approved?

Yes — typically $150-300/month for compounded vs $998-1,349/month for FDA-approved list price. The gap has narrowed because Eli Lilly's LillyDirect now offers Zepbound (FDA-approved tirzepatide) single-dose vials at $349-499/month. For semaglutide specifically, compounded remains 3-6× cheaper than Wegovy or Ozempic, but you trade FDA oversight for cost savings.

Should I switch from compounded to FDA-approved?

It depends on cost vs oversight priorities. Reasons to switch: insurance now covers the FDA-approved version; you experience adverse effects and want clearer regulatory pathway for safety reporting; you're concerned about the narrowing legal basis for compounded GLP-1s. Reasons to stay: cost is the primary access barrier; your current compounder is established and PCAB-accredited; you have a stable, effective regimen. Discuss with your prescriber.

Compounded Semaglutide 2026 — Buyer's Guide (Legal, Safety, Pharmacy Verification)

The 60-second answer

Compounded semaglutide is custom-prepared by state-licensed pharmacies under prescription. It uses the same active ingredient as Wegovy and Ozempic but is NOT FDA-approved as a finished product— meaning FDA has not reviewed the specific formulation for safety, potency, or quality. Cost: $150-300/month vs $1,000-1,800/month for FDA-approved brand. Legal basis narrowed in February 2025 when FDA resolved the semaglutide shortage. Verify any pharmacy by checking state license + PCAB accreditation; avoid “semaglutide sodium” (salt form) which FDA explicitly flagged as unapproved. If cost-driven, compounded remains a meaningful access pathway; if regulatory clarity matters, FDA-approved options are preferable.

1. What is compounded semaglutide?

Compounding is the practice of preparing a custom medication for an individual patient, typically when the FDA-approved commercial product isn't suitable (different dose, allergy to an inactive ingredient, or shortage). Compounding pharmacies operate under state pharmacy law, with federal oversight via the FDA Compounding Quality Act (2013, amending the FD&C Act).

Compounded semaglutide is prepared by a state-licensed pharmacy that combines semaglutide active pharmaceutical ingredient (API) with sterile injection vehicles, typically packaged as multi-dose vials. The pharmacy fills against a specific patient prescription (503A) or in larger outsourcing-facility batches (503B).

Compounded GLP-1 production scaled dramatically in 2023-2024 when FDA placed semaglutide and tirzepatide on its Drug Shortage list. Listing on this database created a legal basis for compounding under Section 503A and Section 503B of the FD&C Act, which restrict compounding of commercially-available drugs except during declared shortages.

2. FDA status: what NOT FDA-approved really means

This phrase causes the most confusion in compounded-GLP-1 marketing. Three distinct things are FDA-regulated:

The active ingredient (semaglutide): FDA-approved, manufactured by FDA-registered API producers, subject to current Good Manufacturing Practices (cGMP).
FDA-approved finished products (Wegovy, Ozempic, Rybelsus): The FDA has reviewed and approved the specific formulation, dose, packaging, and stability data for each of these brand drugs.
Compounded products: NOT individually reviewed or approved by FDA. The pharmacy combines API into a custom preparation; FDA does not verify the potency, sterility, or stability of that specific compounded batch.

This is why “FDA-approved” claims for compounded GLP-1s are misleading. The API is FDA-regulated; the finished compounded preparation is not. State boards of pharmacy and FDA inspections provide oversight of compounding facilities, but the per-batch quality verification that applies to brand products does not apply to compounds.

3. Legal landscape post-shortage (2025-2026)

Timeline of key events:

2022: FDA places semaglutide on Drug Shortage list as Wegovy demand outpaces supply.
2023: Mass compounding of semaglutide scales rapidly via telehealth-pharmacy partnerships.
December 2024: FDA resolves tirzepatide shortage. Lilly demands compounding pharmacies cease production.
February 2025: FDA resolves semaglutide shortage. Major news for compounding industry.
Mid-2025: Multiple lawsuits filed by compounding industry groups challenging FDA resolution; Novo Nordisk separately challenges compounders.
2026: Litigation ongoing; most large compounders have phased down semaglutide-tirzepatide production for new patients while continuing existing patient prescriptions.

Practical effect: traditional 503A compounding for individual patients with specific medical needs (allergy to an inactive ingredient in the brand, custom dose not commercially available, etc.) remains legal. Mass compounding for cost reasons alone is legally precarious post-shortage-resolution.

4. 503A vs 503B pharmacies explained

The two compounding categories under federal law:

503A — Traditional compounding pharmacies

State-licensed pharmacies
Compound against individual patient prescriptions
Cannot mass-produce or sell to other pharmacies/hospitals
Oversight: state Board of Pharmacy + USP standards

503B — Outsourcing facilities

Register voluntarily with FDA
Can produce larger batches without patient-specific prescriptions
Sell to hospitals, clinics, and other pharmacies
Subject to FDA cGMP requirements + inspection
Public list maintained by FDA

Most telehealth compounded GLP-1 programs use 503A pharmacies (per-patient prescriptions) because the 503B path requires stricter cGMP. Some larger operations partner with 503B facilities for higher-quality oversight.

5. The salt-form warning (semaglutide sodium)

The FDA published an alert about “salt” forms of semaglutide, most commonly semaglutide sodium and semaglutide acetate. These are NOT the same as the semaglutide API used in Wegovy/Ozempic (which is the parent semaglutide molecule).

Why this matters: salt forms haven't been studied for safety, potency, or efficacy. Some compounding pharmacies were sourcing cheaper salt-form raw materials from non-FDA-registered suppliers, then compounding them into finished products. The FDA explicitly flagged this practice as unsafe.

What to check: your compounded preparation should be labeled as “semaglutide” — not “semaglutide sodium” or any variant. Ask the pharmacy to confirm which API supplier they use and whether that supplier is FDA-registered.

6. How to verify your pharmacy is legitimate

State license check: Every state Board of Pharmacy maintains a public license lookup tool. Search the pharmacy name + state. Verify the license is active and covers sterile compounding (a separate certification on top of standard pharmacy licensure).
PCAB accreditation:The Pharmacy Compounding Accreditation Board (PCAB) accredits compounding pharmacies that meet voluntary quality standards. Look for “PCAB Accredited” on the pharmacy website or check PCAB's directory. Voluntary, but a meaningful signal.
503B registration (if relevant):If your pharmacy claims to be a 503B outsourcing facility, verify via FDA's 503B Registered Facilities list (public, updated regularly).
USP <797> compliance:Sterile compounding facilities should comply with USP General Chapter <797> standards. Ask the pharmacy if they self-attest compliance.
Real prescription requirement: Any pharmacy shipping compounded GLP-1 without a real prescriber relationship and prescription is operating illegally. Avoid.

7. Cost vs FDA-approved alternatives

As of mid-2026:

Compounded semaglutide: $150-300/month typical via telehealth
Wegovy (FDA-approved semaglutide for weight): $1,349/month list; ~$650/month with NovoCare savings if uninsured
Ozempic (FDA-approved semaglutide for diabetes): $998/month list; often covered by insurance for diabetes
LillyDirect Zepbound vials (FDA-approved tirzepatide for weight): $349-499/month cash-pay

The LillyDirect pricing materially narrowed the cost gap. For weight management specifically, $349/month FDA-approved tirzepatide vs $300/month compounded semaglutide is a meaningfully different cost-benefit calculation than the prior $150 vs $1,349 comparison.

8. Provider landscape: who's offering compounded in 2026

Most large telehealth providers continue to serve existing compounded-semaglutide patients while routing new patients differently:

Hims: Offers compounded semaglutide; also offers Wegovy via partner pharmacies.
Mochi: Continues compounded; emphasizes 503A pharmacy partnerships.
Henry Meds: Compounded semaglutide; transparent about NOT FDA-approved status.
Sequence (Weight Watchers): Has migrated primary focus to FDA-approved Wegovy/Zepbound.
Ro: Primarily FDA-approved focus with some compounded fallback.

See our 12-provider comparison for current pricing, state availability, and which provider fits which user profile.

9. Specific risks of compounded vs brand

Potency variability: Without batch-specific FDA review, potency may differ batch-to-batch. Reputable PCAB-accredited pharmacies test, but variability is documented in published case series.
Sterility: Compounded sterile injections carry sterility risk if facility deviates from USP <797>. Multiple historical compounding contamination outbreaks (most famously NECC meningitis 2012).
Salt-form contamination: Cheap salt-form raw materials remain a risk if pharmacy doesn't verify API supplier.
Adverse event reporting: No standardized post-marketing surveillance system for compounded products like FDA AERS for approved drugs.
Insurance non-coverage: Compounded products are almost never insurance-reimbursable.
Travel + import: Some patients order from non-US pharmacies — legally precarious and quality unclear.

10. When to switch to FDA-approved

Triggers that should prompt a switching conversation with your prescriber:

Your insurance now covers an FDA-approved GLP-1 (commercial plan change, Medicare adding Wegovy CVD coverage, state Medicaid expansion)
LillyDirect or NovoCare pricing brings FDA-approved within 1.5× of compounded cost
You experience an adverse effect and want clearer regulatory pathway for safety reporting
Your current compounder reports supply chain or licensing issues
You're traveling internationally and need an FDA-approved product with broader pharmacy acceptance

Switching is straightforward: same molecule, similar pharmacology. Your prescriber writes a new prescription for the brand product; you continue at the same dose or follow brand-specific titration if dose differs.

11. Frequently asked questions

Is compounded semaglutide FDA-approved?: No. Compounded semaglutide is NOT FDA-approved as a finished product. The FDA approves the active ingredient (semaglutide) and the finished brand products (Wegovy, Ozempic, Rybelsus). Compounded versions use the same active ingredient but the FDA has not reviewed the specific compounded formulation for safety, potency, or quality. Compounding is legal under specific circumstances per 503A and 503B pharmacy rules.
Is compounded semaglutide still legal in 2026?: Yes, compounding under traditional 503A pharmacy rules (per-patient prescriptions) remains legal. The mass-compounding pathway that operated during the 2023-2024 FDA shortage list narrowed substantially after FDA resolved the semaglutide shortage in February 2025. Major telehealth providers continue offering compounded semaglutide for existing patients while increasingly routing new patients to FDA-approved alternatives.
What is the difference between semaglutide and semaglutide sodium?: Semaglutide is the FDA-approved active pharmaceutical ingredient (API). Semaglutide sodium is a salt form that the FDA has explicitly stated is NOT an approved form for compounding. Reputable compounding pharmacies use base semaglutide; salt forms have been flagged by FDA as potentially unsafe due to lack of safety data. Always verify your prescription specifies "semaglutide" (not "semaglutide sodium").
How do I verify a compounding pharmacy is legitimate?: Three checks: (1) Confirm state pharmacy license — every state's Board of Pharmacy has a public license lookup. (2) Look for PCAB accreditation (Pharmacy Compounding Accreditation Board) — voluntary but indicates quality systems. (3) For 503B outsourcing facilities, check FDA's 503B registered facility list. Avoid pharmacies that ship without a real prescription, claim FDA approval of their compound, or sell semaglutide sodium.
Can I get compounded semaglutide cheaper than FDA-approved?: Yes — typically $150-300/month for compounded vs $998-1,349/month for FDA-approved list price. The gap has narrowed because Eli Lilly's LillyDirect now offers Zepbound (FDA-approved tirzepatide) single-dose vials at $349-499/month. For semaglutide specifically, compounded remains 3-6× cheaper than Wegovy or Ozempic, but you trade FDA oversight for cost savings.
Should I switch from compounded to FDA-approved?: It depends on cost vs oversight priorities. Reasons to switch: insurance now covers the FDA-approved version; you experience adverse effects and want clearer regulatory pathway for safety reporting; you're concerned about the narrowing legal basis for compounded GLP-1s. Reasons to stay: cost is the primary access barrier; your current compounder is established and PCAB-accredited; you have a stable, effective regimen. Discuss with your prescriber.

Next steps

Compounded products carry distinct regulatory and quality considerations. Always discuss with your prescriber. This guide is editorial and does not constitute medical advice. GLP1Zoom is affiliate-disclosed. Full disclaimer.